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Introduction
According to the recently updated tumor classification by the World Health
Organization, myelodysplastic syndrome (MDS) constitutes a heterogeneous group
of blood disorders characterized by cytopenia and dysplasia in at least one of the
myeloid lineages.1 MDS is most common in the elderly and is caused by inefficient
hematopoiesis and increased apoptosis within the bone marrow (BM). It is a genet-
ically heterogeneous disorder and individual cases generally harbor two to three
mutations in one of approximately 30 driver genes which are recurrently mutated
in MDS.2,3 Of importance, many of these genes have also been found to be mutated
in acute myeloid leukemia (AML), with frequencies of mutations differing between
the two diseases.2,4 The spectrum of survival of patients with MDS is broad and
high-risk MDS is associated with an increased propensity to progression to AML.5
There has been considerable emphasis on the development of genetically engi-
neered mouse models in attempts to study MDS. These include strains harboring
lesions in the most commonly mutated genes in MDS, such as SF3B1,6 TET2,7,8
ASXL19 and SRSF2.10 The phenotypic properties of these models have been
reviewed in detail previously11-13 and although they all present with several pheno-
typic features of MDS, they clearly have some limitations with respect to their abil-
ities to recapitulate human MDS biology. As an example, Sf3b1K700E mutant mice
develop anemia and display expansion of the long-term hematopoietic stem cell
compartment, consistent with an MDS phenotype. However, the Sf3b1K700E mutant
line fails to present with ring sideroblasts which are normally found in patients with
SF3B1 mutations.14 Another likely contributor to the inability of current genetically
engineered mouse model lines to fully recapitulate the phenotypic spectrum of MDS
is the fact that most models typically harbor one genetic lesion and, therefore, not
the full mutational complement observed in MDS patients. Thus, there is a clear
need for better models of MDS biology, including patient-derived xenografts (PDX),
in order to recapitulate the disease’s biology and complexity better. 
The history of myelodysplastic syndrome patient-derived xenografts
The first PDX models of AML were established more than 40 years ago by sub-
cutaneously engrafting patient material into immune-deprived mice.15 More physi-
ologically relevant models were developed over the next decade via the use of tail
vein injection and improved immune-deficient strains.16,17 In contrast, it was not
until the beginning of this millennium that cells from MDS patients were demon-
strated to engraft functionally in immune-compromised mice.18-20 However, only
cells from a limited number of patients could be engrafted and a study with a large
number of patients demonstrated that engraftment was sustained by residual nor-
mal cells and not by the MDS clone(s).21 During the last decade, several laboratories
have published a number of complementary approaches for the generation of MDS
PDX.22-34 Importantly, these combined efforts have demonstrated the engraftment
capacity of most MDS subtypes,23-28,34 that the expanded cells retain the genetic and
phenotypic features of the primary tumor,24-27,29,30,32,34 that these PDX models also sus-
tain engraftment in secondary recipients24,27,29,34 and that they allow evaluation of
new therapies.32,33 Nevertheless, as summarized in Table 1 and Figure 1, these mod-
els are quite heterogeneous. Specifically, several immune-compromised murine
strains have been used (NOG, NSG, NSG-S or MISTRG) and injected at different
ages (from newborn pups to adult animals). Moreover, a number of different cell
Table 1. Summary of published patient-derived xenograft models from myelodysplastic syndrome patients.
                                                                                         Mice                                                                   MDS patient cells 
Year        Reference              Strain                   Age            Irradiation?         Injection     MDS subtype /       Injected              Cell               MSC     Patients  Expansion
                                                                                                                          route              features               cells             numbers    co-injected?tested  time (weeks)
2002       Nilsson et al.18   NOD/LtSz-SCID or    8-12 weeks                yes,                   tail vein            trisomy 8+           BM CD34+          1.68-5 x105              No               3         6 - 8 weeks
                                               NOD/LtSz-SCID                                     350-375 cGy                                                                       BM CD34+           1-1.4x104                No
                                                        β2m-/-                                                                                                                                                                                                                                            CD38-
2003        Benito et al.21           NOD/SCID             6-8 weeks      300-350-375 cGy     tail i.v or i.p             15 RA,                BM cells          0.4-3.5x107              No              37                n.s
                                                                                                                                                                                11 RAEB, 
                                                                                                                                                                                 6 RAEBt,
                                                                                                                                                                                  5 RARS
2004  Thanopoulou et al.20    NOD/-SCID           8-10 weeks        yes, 350 cGy       tail vein or i.p             1 RA,                 BM cells            4-17x106                No              11        5-23 weeks
                                                      β2m-/- or                                                                                                            1 RARS, 
                                                   NOD/-SCID                                                                                                        2 RAEB,
                                                β2m-/-3/GM/SF                                                                                                    3 RAEBT, 
                                                                                                                                                                                 4 CMML
2004      Kerbauy et al.19         NOD/-SCID                   n.s                        n.s                intrafemoral                n.s                 BM MNC +         107 MNC              yes,              6         4-17 weeks
                                                        β2m-/-                                                                                                                                      MSC cell lines      + 105 HS5           HS5 &
                                                                                                                                                                                                          HS5 & HS27a        & HS27a            HS27a
2010        Martin et al.37                 NSG                          n.s                       yes,          i.v. (retro-orbital)     low risk               BM cells          5x105-5x106             No               5         7-12 weeks
                                                                                                                     250 cGy           or intra-tibial                                        BM cells            1.8-5x106                                    5                   
                                                                                                                                                                                                                 T cells                                                                                       
                                                                                                                                                                                                               depleted
                                                                                                                                          i.v. (retro-orbital)                              BM cells CD34+    5x105/2x106                                  3                   
2011    Muguruma et al.22            NOG                         n.s                       yes,               intrafemoral      3 RA, 3 RAEB,         BM CD34+           1.4-5x105               Yes               6                 n.s
                                                                                                                    250 cGy                                             5 RAEB-T                      
2013          Pang et al.23                  NSG              P0-P3 newborn       sublethal              anterior               low risk               HSC-like            1.5-3x103                No               4                 16
                                                                                         pups               (100 rads)           facial vein       (monosomy 7)       (Lin-CD34+
                                                                                                                                                                                                             CD38-CD90+
                                                                                                                                                                                                               CD45RA-)
2014      Medyouf et al.24     NSG or NSG-S          6-8 weeks         yes, 200 cGy          intrabone               low or               BM CD34+                 105                    Yes              20       16-28 weeks
                                                                                                                                                                            intermediate        + BM MSC
                                                                                                                                                                                     risk                           
2015         Mian et al.25        NSG (females)        8-12 weeks        yes, 375 cGy    intra-BM (tibia)          RARS                BM CD34+           0.65-2 105               No               4        18-20 weeks
2017      Rouault-Pierre     NSG or NSG-S                n.s            yes, 330-375 cGyintra-BM (tibia)       8 RCMD,                 CD34+                1-2x105                Yes                         12-18 weeks
                       et al.26                                                                                                                                          3 RCMD-RS,           BM cells       (1:1 for MSC)
                                                                                                                                                                          7 RAEB, 6 RARS,            +/- 
                                                                                                                                                                             1 MDS/MPN,           BM MSC                                                               28                  
                                                                                                                                                                                 3 CMML
                                                                                                                                                                                                           CD3- BM cells       106 CD3-              Yes
                                                                                                                                                                                                           +/- BM MSC    (2:1 for MSC)
                                                                                                                                                                                                          ( 2:1 for CD3-)                                                            
2017       Yoshimi et al.27             NSG-S                6-10 weeks    yes, 200-250 cGy    intrafemoral            CMML               BM CD34+         0.2-1.18x106             No               8         3-11 weeks
                                                                                                                                                     tail i.v                  JMML                BM or PB     2.2-4x106 (BM)         No               4          2-7 weeks
                                                                                                                                                                                                                   MNC        or 1.3-2x106 (PB)
2017        Zhang et al.28        NSG or NSG-S          6-8 weeks         yes, 250 cGy   i.v. (retro-orbital)       CMML                   BM or           3x104-1.2x106            No              16       10-16 weeks
                                                                                                                                                                                                               PB CD34+                    
2018      Krevvata et al.29      NSG or NSG-S          6-8 weeks          yes, 250cGy        intrafemoral         3 low-risk,             BM MNC         106 BM MNC           Yes               7         8-32 weeks
                                                                                                                                                                               4 high-risk                  +/-                     +/-
                                                                                                                                                                                                                BM MSC         105 BM MSC
2018      Meunier et al.30               NSG                  8-12 weeks        no, 25mg/kg           intra-BM              1 RAEB,              CD34+ BM        5x105 CD34+            Yes               4           6 months
                                                                                                              busulfan d-1 i.p         (tibia)               2 RAEB1,            cells + BM         & 1.5x106                 
                                                                                                                                                                                  1 RARS                   MSC              MSC (1:3)                 
2018       Shastri et al.31                NSG                          n.s                yes, 200cGy              tail i.v              2 int-2 risk,         BM/PB MNC           2-5x106                 No               4            3 weeks
                                                                                                                                                                              1 high-risk, 
                                                                                                                                                                                   1 MPN
2018       Stevens et al.32              NSG-S                        n.s                no, 25mg/kg              tail i.v              8 high-risk             BM MNC            0.8-1x106                No               4         6-10 weeks
                                                                                                                 busulfan d-1
2019         Smith et al.33                 NSG                          n.s                yes, 200cGy              tail i.v          U2AF1 mutants         BM MNC              2-5x106                 No               2            3 weeks
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2019         Song et al.34       MISTRG or NSG          1-3 days         yes, 2x150cGy   intrahepatically      1 del(5q),            BM CD34+         0.2-2.75x105             No              22       12-31 weeks   
                                                                                                                (MISTRG) or                                         3 MLD,                        
                                                                                                             1x100cGy (NSG)                                    2 RS-SLD, 
                                                                                                                                                                               1 RS-MLD, 
                                                                                                                                                                             1 MPN-RS-T, 
                                                                                                                                                                            3 EB-1, 3 EB-2                  
                                                                                                                                                                           1 MLD, 2 EB-1,         BM CD3-           1.15-6x105              No               4        13-15 weeks
                                                                                                                                                                                   1 EB-2                         
The main characteristics of the protocols published to generate patient-derived xenograft (PDX) models from patients with myelodysplastic syndromes (MDS) are presented. NOD/SCID: non-
obese diabetic mice with Prkdcscid mutation; β2m-/-: beta2-microglobulin null; 3/GM/SF: constitutive expression of human interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor
(GM-CSF) and stem cell factor (SF); NOG: NOD/Shi-scid Il2rgnull; NSG: NOD.Cg- Prkdcscid Il2rgnull;; NSG-S: NSG with human IL-3, GM-CSF and SF constitutive expression; MISTRG: humanized
macrophage colony-stimulating factor, IL-3/GM-CSF, SIRP alpha and thrombopoietin combined with Rag2-/-, IL2Rg-/-; i.v.: intravenous injection; i.p: intraperitoneal injection; cGy: centigray; BM: bone
marrow; PB: peripheral blood; MNC: mononuclear cells; MSC: mesenchymal stromal cells; HSC: hematopoietic stem cells; Lin-: lineage negative; RA: refractory anemia; RAEB: refractory anemia
with excess blasts; RAEB-I: RAEB type 1; RAEB-II: RAEB type 2; RAEBt: RAEB in transformation; RARS: refractory anemia with ringed sideroblasts; RARS-T: RARS with thrombocytosis; RS: ringed
sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RCMD-RS: RCMD and ringed sideroblasts; del(5q): MDS associated with isolated deletion of chromosome 5q; MDS/MPN:
myelodysplastic/myeloproliferative neoplasms; CMML: chronic myelomonocytic leukemia;  JMML: juvenile myelomonocytic leukemia; MLD: multilineage dysplasia; SLD: single lineage dysplasia;
EB: excess blasts; MDS/MPN-RS-T: MDS/MPN with ring sideroblasts and thrombocytosis; n.s.: not specified.
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sources have been employed (BM or peripheral blood
mononuclear cells, CD3-depleted BM cells, CD34+ BM
cells) which were injected in different quantities, in the
presence or absence of BM-derived mesenchymal stromal
cells (MSC) and in different anatomical locations (intra-
venous, intrafemoral, intrahepatic). Not surprisingly, this
resulted in very different disease latencies (from 3 to 32
weeks post-injection). A number of conclusions can be
drawn from this extensive work: 
(i) With respect to selection of the recipient strain, an
immunodeficient background is necessary. The most com-
monly used recipient for the generation of PDX is the
NSG strain which harbors mutations in Prkdc and Il2g
leading to the absence of B, T  and NK cells.35 The consti-
tutive expression of the human cytokines interleukin-3 (Il-
3), granulocyte-macrophage colony-stimulating factor
(GM-CSF) and stem cell factor (SCF) on this background
(NSG-S, also designated NSG-SGM3) does not lead to
enhanced engraftment of most MDS subtypes, except for
chronic myelomonocytic leukemia,28 in contrast to the sit-
uation in AML.24,26,29,36 On the other hand, the recently
developed MISTRG strain, expressing human macrophage
colony-stimulating factor (M-CSF), IL-3, GM-CSF, signal
regulatory protein alpha (SIRPα) and thrombopoietin at
physiological levels on a different immunodeficient back-
ground (Rag2-/-, IL2Rg-/-), was recently demonstrated to be
a promising host for engraftment of MDS patients’ mate-
rial.34 Not only could cells from patients with various sub-
types of MDS be expanded in this line, but the levels of
engraftment were increased, with a higher percentage of
CD33+ myeloid cells than in NSG mice. Moreover, long-
term engraftment of these myeloid cells was also
improved in this strain as CD33+ cells constituted more
than 80% of the hCD45+ compartment in secondary recip-
ients, compared to 30% in NSG mice. Additionally, MDS
cells engrafted in MISTRG mice generated erythroid and
megakaryocytic lineages at a higher frequency than in the
NSG counterpart.34
(ii) T-cell depletion of the primary MDS tumor, either by
treatment with a human CD3 antibody or by physical
separation, is a prerequisite to limit graft-versus-host dis-
ease.26,34,36-38 Indeed, one of the first attempts to generate
MDS PDX failed mainly because of the predominant
growth of human CD3+ T cells, leading to graft-versus-host
disease in most of the recipient animals.37
(iii) Intrafemoral injections result in better engraftment in
NSG mice compared to an intravenous route of injection.
(iv) Co-injection of MSC leads to variable results in
terms of promoting the engraftment of MDS samples,
with some laboratories reporting some enhancement,22-24
whereas others have not found this effect.26,29 The under-
lying reasons for this variation are not clear. However, as
human MSC only survive for 2-4 weeks in the murine
BM,24,26 this variation could potentially reflect patient-
specific differences in the ability of MSC to promote the
initial seeding and engraftment of MDS cells in the
murine BM. 
(v) Engraftment capacity does not seem to be related to
MDS subtypes, but rather appears to be specific to the
individual samples, as indicated in studies with large num-
bers of patients.24,26,34
Alternative strategies
Despite extensive efforts in several laboratories, this
cumulative work has only produced a total of approxi-
mately 100 MDS PDX so far. There is, therefore, a strong
need for alternative systems that could enhance the gener-
ation of MDS PDX. Interestingly, descriptions of a number
of humanized bone marrow-like structure (hBMLS) mod-
els have been published recently. These models enable the
expansion of AML patients’ cells that failed to engraft
with conventional methods.39-41 They are all based on the
use of BM MSC and can be separated into two categories.
In the first category, which we will define as “scaffold”
models, in vitro-expanded MSC are seeded in a gelatin
sponge and cultured for a couple of days. Next, human
leukemic cells are injected into the sponge which is subse-
quently introduced subcutaneously into non-irradiated
immunocompromised mice41 (Figure 1). In the second
approach, BM MSC are first mixed with Matrigel and
introduced subcutaneously into immune-deficient mice in
which they develop a so-called “ossicle” after 2-3 months,
which constitutes an exterior bone structure surrounding
a hematopoietic core. Following sublethal irradiation,
human leukemic cells are injected into the ossicle where
they expand39 (Figure 1). Another ossicle-like approach
combines osteogenic priming of MSC with a physical sup-
port consisting of two or three biphasic calcium phos-
phate particles, prior to subcutaneous insertion into mice
and subsequent ossicle development.40 Importantly, up to
four hBMLS per animal can be introduced,39-41 and Reinisch
et al. have elegantly demonstrated that tumor cells can cir-
C. Côme et al.
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culate between ossicles leading to engraftment of
leukemic cells in non-injected hBMLS, thereby allowing
for increased expansion of the original material from
patients.39
In the previously described MDS PDX models, engraft-
ment and expansion of the MDS material occur mainly in
the recipient BM. In contrast, the hBMLS approaches
exploit a humanized version of the BM niche, since at
least bone, cartilage and MSC present in the niche are of
human origin.42 Of note, these hBMLS constitute a prefer-
ential homing niche for leukemic cells when compared to
murine BM because leukemic cells injected intravenously
expand earlier and at higher frequency in hBMLS than in
the BM of mice.39,40 Moreover, as the BM microenviron-
ment has been reported to play an important role in the
onset and development of MDS as well as the response to
therapy, these hBMLS models are likely to be superior in
mimicking key disease parameters.43,44
Is a standardized approach possible?
As discussed above, a plethora of approaches has been or
could be used to generate PDX from MDS patients (Table
1 and Figure 1). However, these approaches are quite het-
erogeneous, and use different murine strains, injection
sites, types and numbers of cells injected. In order to facil-
itate a comparison between different studies, it would be
helpful if the field could agree on a more limited set of
robust experimental protocols. In our opinion, two options
are quite attractive. Our first candidate is the MISTRG
model which has been demonstrated to mediate the
engraftment of material from patients with different sub-
types of MDS and appears relatively simple to implement.
Moreover, in the published research, in which patients’
cells have been injected intrahepatically into irradiated
pups, this line appears to be superior to NSG in terms of
engraftment frequency and myeloid percentages.34 One
note of caution is the reported development of anemia in
this strain, which is also a characteristic of human MDS.45,46
This may potentially make it complicated to determine
whether the anemia observed in MDS PDX is caused by
defects in MDS hematopoietic stem cells or by the intrinsic
phenotype of the MISTRG strain. Moreover, the intrahep-
atic route of injection in newborn pups may not only raise
some logistic challenges, but could also potentially influ-
ence tumor behavior, because this system constitutes a
“young” niche, in contrast to the BM niche of elderly MDS
patients. It is to be hoped that further generation of
AML/MDS PDX with this mouse model by additional lab-
oratories will strengthen the relevance of this model.
Even though the ossicle strategy is extremely seducing
as it allows engraftment of patients’ cells into a mature
humanized BM-like environment, our own experience
indicates that a very high proportion of MSC batches fail
to sustain ossicle development (11/12, unpublished observa-
MDS PDX: from no options to many
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Figure 1. Key features of published and alternative patient-derived xenograft models of myelodysplastic syndrome. The left panel depicts the sources of cells from
patients with myelodysplastic syndrome (MDS) which are injected to generate MDS patient-derived xenografts. Tumor cells (red circles) are constituted of bone mar-
row (BM) cells, mononuclear cells (MNC), or CD34+ purified or T-cell depleted BM cells. Supporting cells (yellow) are BM-derived mesenchymal stromal cells (MSC)
derived from patients or healthy donors. The time periods for ossicle development and engraftment of MDS cells are illustrated by light and dark gray bars, respec-
tively. The time of conditioning of the animal, by either irradiation or busulfan treatment is indicated, and the injection route is illustrated by a syringe.
tions). Moreover, to our knowledge, AML PDX models
based on this approach have only been described by one
laboratory so far.39,42 Therefore, our second proposed
model is hBMLS based on gelatin scaffolds. This tech-
nique is quite simple and, as for ossicles, up to four scaf-
folds can be inserted per animal. Moreover, this strategy
does not involve a long period of in vivo incubation in
order to generate ossicles and, importantly, does not
require pre-conditioning with irradiation.41 Using this
technique, we have succeeded in generating MDS PDX
models covering several MDS subtypes in both our labo-
ratories. A limitation of this approach, as for other hBMLS
models, is the use of BM-derived MSC because these
MSC have various alterations compared to those derived
from healthy donors, such as DNA methylation status47,48
and in vitro proliferation/differentiation capacity.47 There is
therefore a risk that the use of healthy allogeneic MSC
may affect the behavior of the MDS clone(s) in vivo.
Encouragingly, the few studies that have compared the
use of healthy and patient-specific MSC have not suggest-
ed a major impact of the MSC origin on the engraftment
levels of MDS in immunocompromised mice receiving
intra-femoral injections.26,29 Nevertheless, MDS-derived
BM MSC do have an impact on the survival and differen-
tiation capacities of CD34+ hematopoietic stem and pro-
genitor cells in vitro and in vivo,47,49 and they can also
respond favorably to the hypomethylating agent azacyti-
dine, the current treatment regimen for high-risk MDS.49
Consequently, investigation are needed to determine
whether autologous MDS-BM MSC would be better at
recapitulating the complexity of the disease in this model
rather than BM MSC from healthy donors.
A major unresolved issue for the hBMLS approaches is
that MSC display significant donor-to-donor variations and
it would therefore be extremely useful to have a standard-
ized source of MSC, i.e. in the form of BM MSC lines.
Importantly, such cell lines have been generated recently and
it would be of paramount importance to determine whether
they retain their capacity to generate hBMLS in vivo50 and
whether MDS material could engraft and expand in these
structures. As MDS MSC have been shown to have a strong
impact on the in vivo potential of CD34+ hematopoietic stem
and progenitor cells, notably by showing altered extracellu-
lar signaling such as reduced CXCL12 expression,48,49 such a
cell line should either retain the features of MDS MSC or be
receptive to “education” by MDS cells. However, if a MSC
cell line that robustly retains these features could be
obtained, this would provide an experimental platform for
genetic manipulation of niche-derived cells, thereby facilitat-
ing studies into niche-MDS cell interactions.
Conclusions and perspectives
MDS is a very heterogeneous group of blood disorders,
associated with lesions in dozens of driver genes.2,3
Genetically engineered mouse models harboring muta-
tions in the most common MDS driver genes display sev-
eral characteristics of MDS11-13 but remain imperfect as an
experimental tool since they generally only recapitulate a
subset of the phenotypes associated with human MDS.
During the past few decades, in particular during the past
5 years, we have seen several improvements in the tool-
box available for the generation of MDS PDX.18-20,22-27,29,31,34
Moreover, various alternative methods, especially hBMLS
models, appear to be extremely promising in terms of
facilitating a more robust generation of MDS PDX.39-41 This
is important since an increase in the number of MDS PDX
models will allow us to cover the broad genetic and phe-
notypic spectra of human MDS more comprehensively
and provide tools to address key aspects of MDS biology. 
Despite the recent developments in MDS PDX, these
models may be further improved by incorporating addi-
tional human niche cells, such as endothelial cells. Indeed,
these cells are functional in hBMLS settings51,52 and
endothelial cells from low-risk MDS patients influence
hematopoietic stem cell behavior in vitro.53 However, the
recent developments of hBMLS models already provide an
excellent opportunity to characterize the interaction
between MDS tumor cells and their microenvironment
better. As indicated above, the tumor microenvironment
plays a key role in the pathogenesis of MDS and if we
could manipulate MSC in the hBMLS models, we would
have a precise tool to discern the biological importance of
the niche. Finally, the increasing armory of MDS PDX also
holds great promise as preclinical translational models for
the development and validation of novel therapies as well
as for personalized medicine along the lines already occur-
ring in solid cancers.
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